This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.

The “Hidradenitis Suppurativa: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Hidradenitis Suppurativa.

The “C3 Glomerulopathy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of C3 Glomerulopathy.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Refractory Gout.

The global treg therapy market size, valued at USD 22 million in 2025, is projected to reach USD 47 million in 2026 and USD 442 million by 2035, representing a CAGR of 28.1% during the forecast period. Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T cells (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-onco...

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Giant Cell Arteritis.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Spinocerebellar Ataxias.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities

The anti CD47 drugs market size is estimated to be worth $0.1 billion in 2023 and is expected to grow at CAGR of 42.9% till 2035. The National Cancer Institute (NCI) has estimated that, by 2030, over 22 million individuals are likely to be diagnosed with various types of cancer, in the US alone. As a result of the growing patient population affected by this disease, there is a rise in the demand for effective treatment modalities. Therefore, in recent years, the focus of the research community h...

The global pharmaceutical vials market, valued at USD 11.65 billion in 2025, is projected to reach USD 12.33 billion in 2026 and USD 15.85 billion by 2030, with a 6.5% CAGR during the forecast period, 2026 to 2030. Pre-sterilized / ready-to-use (RTU) pharmaceutical vials have emerged as a promising alternative to conventional pharmaceutical vials, adding significant value to streamline pharmaceutical fill / finish operations. It is worth noting that these innovations have significantly helped in...

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of TIGIT Inhibitor.

The global bioprocess automation market is estimated to grow from USD 6.5 billion in 2025 to reach USD 10.6 billion by 2030, representing a higher CAGR of 10.0% during the forecast period. Given the various advantages of controllers and automated systems, biopharmaceutical developers and manufacturers are steadily adopting such solutions. Moreover, the recent surge in demand for vaccines amidst the ongoing COVID-19 pandemic has also prompted the biopharmaceutical companies to develop automation...

The “Cholangiocarcinoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Cholangiocarcinoma.

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Ankylosing Spondylitis.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Thoracic Aortic Aneurysm.

The Fc fusion therapeutics market is estimated to be worth $15.5 billion in 2022 and is expected to grow at CAGR of 10% during the forecast period. In March 2026, Shanghai Henlius Biotech dosed the first patient in a phase 1b / 2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and chemotherapy for advanced RAS / BRAF wild-type metastatic colorectal cancer in China.